A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension (ZEAL Part B)

  • Braude, Michael (Primary Chief Investigator (PCI))

Project: Research

Project Details

Effective start/end date22/05/2421/05/29